RSV Diagnostics Market by Product (Kits and Assays, Instruments), Method (Rapid Antigen Detection Test (Immunofluorescence Assay, ELISA), Molecular Diagnostic), End User (Hospitals & Clinics, Clinical Laboratories, Homecare) - Global Forecast to 2022
“The global RSV diagnostics market projected to grow at a CAGR of 10.1% during the forecast period”
The RSV diagnostics market is expected to reach USD 929.2 million by 2022 from USD 574.3 million in 2017, at a CAGR of 10.1%. Factors driving the growth of this market include rising burden of RSV infections, growing demand for molecular diagnostic tests for the diagnosis of RSV infections, increasing adoption of point-of-care testing for RSV diagnosis and increasing approval of RSV diagnostic kits and assays. On the other hand, the development of RSV vaccine is expected to emerge as a biggest threat which would alter the market growth in the coming years.
“Kits and Assays are estimated to grow at the highest CAGR during the forecast period”
The products market is further segmented into kits and assays, instruments, and other products. The kits and assays segment is expected to account for the largest share and grow at the highest CAGR during the forecast period. Factors driving the growth of this segment include the increasing infection of RSV in newborn infants and young children and growing demand for kits and assays for RSV diagnosis
“The molecular diagnostics segment is estimated to grow at the highest CAGR during the forecast period”
The method market is further segmented into Rapid Antigen Detection Tests, molecular diagnostics, and others methods. The molecular diagnostics segment is expected to account for the largest share of the global RSV diagnostics market in 2017. Market growth can largely be attributed to factors such as the increasing demand for molecular diagnostic testing for RSV diagnosis.
“Asia Pacific is estimated to grow at the highest CAGR during the study period”
Geographically, the RSV diagnostics market is dominated by North America, followed by Europe in 2017. Asia Pacific is estimated to grow at the fastest rate, due to increasing infectious disease burden such as RSV infection, increasing demand for RSV disease diagnosis, and increasing healthcare expenditure in APAC countries.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage:
The report analyses the RSV diagnostics market by product, method, end user, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers growth strategies adopted by industry players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful.
Key Benefits of Buying the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report can use one or a combination of the below mentioned five strategies for strengthening their market shares.
The report provides insights on the following pointers:
The RSV diagnostics market is expected to reach USD 929.2 million by 2022 from USD 574.3 million in 2017, at a CAGR of 10.1%. Factors driving the growth of this market include rising burden of RSV infections, growing demand for molecular diagnostic tests for the diagnosis of RSV infections, increasing adoption of point-of-care testing for RSV diagnosis and increasing approval of RSV diagnostic kits and assays. On the other hand, the development of RSV vaccine is expected to emerge as a biggest threat which would alter the market growth in the coming years.
“Kits and Assays are estimated to grow at the highest CAGR during the forecast period”
The products market is further segmented into kits and assays, instruments, and other products. The kits and assays segment is expected to account for the largest share and grow at the highest CAGR during the forecast period. Factors driving the growth of this segment include the increasing infection of RSV in newborn infants and young children and growing demand for kits and assays for RSV diagnosis
“The molecular diagnostics segment is estimated to grow at the highest CAGR during the forecast period”
The method market is further segmented into Rapid Antigen Detection Tests, molecular diagnostics, and others methods. The molecular diagnostics segment is expected to account for the largest share of the global RSV diagnostics market in 2017. Market growth can largely be attributed to factors such as the increasing demand for molecular diagnostic testing for RSV diagnosis.
“Asia Pacific is estimated to grow at the highest CAGR during the study period”
Geographically, the RSV diagnostics market is dominated by North America, followed by Europe in 2017. Asia Pacific is estimated to grow at the fastest rate, due to increasing infectious disease burden such as RSV infection, increasing demand for RSV disease diagnosis, and increasing healthcare expenditure in APAC countries.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1–43%, Tier 2–35%, Tier 3–22%
- By Designation: C level–62%, Director level–21%, Others–17%
- By Region: North America–32%, Europe–27%, Asia Pacific–22%, Rest of World –19%
Research Coverage:
The report analyses the RSV diagnostics market by product, method, end user, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers growth strategies adopted by industry players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful.
Key Benefits of Buying the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report can use one or a combination of the below mentioned five strategies for strengthening their market shares.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the RSV diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the RSV diagnostics market.
- Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the RSV diagnostics market.
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various tissue diagnostics products and services across geographies.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the RSV diagnostics market.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 SCOPE OF THE STUDY
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.3.2 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of Primary Interviews, by Company Type, Designation, and Region
2.1.3 KEY DATA FROM PRIMARY SOURCES
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES IN THE RSV DIAGNOSTICS MARKET
4.2 GEOGRAPHIC ANALYSIS: RSV DIAGNOSTICS MARKET, BY PRODUCT & REGION (2017)
4.3 RSV DIAGNOSTICS MARKET, BY END USERS, 2017–2022
4.4 GEOGRAPHICAL SNAPSHOT OF THE RSV DIAGNOSTICS MARKET
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing burden of RSV infections
5.2.1.2 Growing demand for point-of-care molecular diagnostic tests for the diagnosis of RSV infections
5.2.1.2.1 Increasing adoption of molecular diagnostics over immunoassays
5.2.1.3 Increasing approval of RSV diagnostic kits and assays
5.2.2 RESTRAINTS
5.2.2.1 Low detection limits of immunoassays
5.2.3 OPPORTUNITIES
5.2.3.1 Technological advancements in diagnostic methods
5.2.4 THREATS
5.2.4.1 Development of RSV vaccines
6 RSV DIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 KITS AND ASSAYS
6.3 INSTRUMENTS
6.4 OTHER PRODUCTS
7 RSV DIAGNOSTICS MARKET, BY METHOD
7.1 INTRODUCTION
7.2 MOLECULAR DIAGNOSTICS
7.3 RAPID ANTIGEN DETECTION TESTS
7.3.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS
7.3.2 IMMUNOFLUORESCENCE ASSAYS
7.3.3 OTHER RAPID ANTIGEN DETECTION TESTS
7.3.3.1 Chromatographic immunoassays
7.3.3.2 Optical immunoassays
7.4 OTHER METHODS
8 RSV DIAGNOSTICS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS AND CLINICS
8.3 CLINICAL LABORATORIES
8.4 HOME CARE
9 RSV DIAGNOSTICS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 UK
9.3.3 FRANCE
9.3.4 REST OF EUROPE
9.4 APAC
9.5 ROW
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 MARKET OVERVIEW
10.3 MARKET SHARE ANALYSIS, 2016
10.4 COMPETITIVE SCENARIO
10.4.1 PRODUCT LAUNCHES AND APPROVALS
10.4.2 ACQUISITIONS
10.4.3 AGREEMENTS AND COLLABORATIONS
10.4.4 EXPANSIONS
11 COMPANY PROFILES
Business Overview, Products Offered, Recent Developments, MNM View
11.1 BIOM?RIEUX
11.2 BECTON, DICKINSON AND COMPANY (BD)
11.3 ABBOTT
11.4 ROCHE
11.5 DANAHER
11.6 THERMO FISHER
11.7 BIOCARTIS
11.8 LUMINEX
11.9 HOLOGIC
11.10 FAST TRACK DIAGNOSTICS
*Details might not be captured in case of unlisted companies.
12 APPENDIX
12.1 INDUSTRY INSIGHTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
12.5 AVAILABLE CUSTOMIZATIONS
12.6 RELATED REPORTS
12.7 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 SCOPE OF THE STUDY
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.3.2 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of Primary Interviews, by Company Type, Designation, and Region
2.1.3 KEY DATA FROM PRIMARY SOURCES
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES IN THE RSV DIAGNOSTICS MARKET
4.2 GEOGRAPHIC ANALYSIS: RSV DIAGNOSTICS MARKET, BY PRODUCT & REGION (2017)
4.3 RSV DIAGNOSTICS MARKET, BY END USERS, 2017–2022
4.4 GEOGRAPHICAL SNAPSHOT OF THE RSV DIAGNOSTICS MARKET
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing burden of RSV infections
5.2.1.2 Growing demand for point-of-care molecular diagnostic tests for the diagnosis of RSV infections
5.2.1.2.1 Increasing adoption of molecular diagnostics over immunoassays
5.2.1.3 Increasing approval of RSV diagnostic kits and assays
5.2.2 RESTRAINTS
5.2.2.1 Low detection limits of immunoassays
5.2.3 OPPORTUNITIES
5.2.3.1 Technological advancements in diagnostic methods
5.2.4 THREATS
5.2.4.1 Development of RSV vaccines
6 RSV DIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 KITS AND ASSAYS
6.3 INSTRUMENTS
6.4 OTHER PRODUCTS
7 RSV DIAGNOSTICS MARKET, BY METHOD
7.1 INTRODUCTION
7.2 MOLECULAR DIAGNOSTICS
7.3 RAPID ANTIGEN DETECTION TESTS
7.3.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS
7.3.2 IMMUNOFLUORESCENCE ASSAYS
7.3.3 OTHER RAPID ANTIGEN DETECTION TESTS
7.3.3.1 Chromatographic immunoassays
7.3.3.2 Optical immunoassays
7.4 OTHER METHODS
8 RSV DIAGNOSTICS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS AND CLINICS
8.3 CLINICAL LABORATORIES
8.4 HOME CARE
9 RSV DIAGNOSTICS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 UK
9.3.3 FRANCE
9.3.4 REST OF EUROPE
9.4 APAC
9.5 ROW
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 MARKET OVERVIEW
10.3 MARKET SHARE ANALYSIS, 2016
10.4 COMPETITIVE SCENARIO
10.4.1 PRODUCT LAUNCHES AND APPROVALS
10.4.2 ACQUISITIONS
10.4.3 AGREEMENTS AND COLLABORATIONS
10.4.4 EXPANSIONS
11 COMPANY PROFILES
Business Overview, Products Offered, Recent Developments, MNM View
11.1 BIOM?RIEUX
11.2 BECTON, DICKINSON AND COMPANY (BD)
11.3 ABBOTT
11.4 ROCHE
11.5 DANAHER
11.6 THERMO FISHER
11.7 BIOCARTIS
11.8 LUMINEX
11.9 HOLOGIC
11.10 FAST TRACK DIAGNOSTICS
*Details might not be captured in case of unlisted companies.
12 APPENDIX
12.1 INDUSTRY INSIGHTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
12.5 AVAILABLE CUSTOMIZATIONS
12.6 RELATED REPORTS
12.7 AUTHOR DETAILS
LIST OF TABLES
Table 1 CURRENT STATUS OF RSV VACCINES
Table 2 RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 3 RSV DIAGNOSTICS MARKET FOR KITS AND ASSAYS, BY REGION, 2015–2022 (USD MILLION)
Table 4 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR KITS AND ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 5 EUROPE: RSV DIAGNOSTICS MARKET FOR KITS AND ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 6 RSV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2015–2022 (USD MILLION)
Table 7 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 8 EUROPE: RSV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 9 RSV DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2015–2022 (USD MILLION)
Table 10 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 11 EUROPE: RSV DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 12 RSV DIAGNOSTICS MARKET, BY METHOD, 2015–2022 (USD MILLION)
Table 13 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 14 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 15 EUROPE: MOLECULAR DIAGNOSTIC MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 16 RAPID ANTIGEN DETECTION TESTS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 17 RAPID ANTIGEN DETECTION TESTS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 18 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 19 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 20 RAPID ANTIGEN DETECTION TESTS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2015–2022 (USD MILLION)
Table 21 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 22 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 23 RAPID ANTIGEN DETECTION TESTS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY REGION, 2015–2022 (USD MILLION)
Table 24 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 25 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 26 OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 27 OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 28 NORTH AMERICA: OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 29 EUROPE: OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 30 RAPID ANTIGEN DETECTION TESTS MARKET FOR CHROMATOGRAPHIC IMMUNOASSAYS, BY REGION, 2015–2022 (USD MILLION)
Table 31 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR CHROMATOGRAPHIC IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 32 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR CHROMATOGRAPHIC IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 33 RAPID ANTIGEN DETECTION TESTS MARKET FOR OPTICAL IMMUNOASSAYS, BY REGION, 2015–2022 (USD MILLION)
Table 34 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR OPTICAL IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 35 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR OPTICAL IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 36 OTHER METHODS MARKET FOR RSV DIAGNOSTICS, BY REGION, 2015–2022 (USD MILLION)
Table 37 NORTH AMERICA: OTHER METHODS MARKET FOR RSV DIAGNOSTICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 38 EUROPE: OTHER METHODS MARKET FOR RSV DIAGNOSTICS, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
Table 39 RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 40 RSV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2015–2022 (USD MILLION)
Table 41 NORTH AMERICA: RSV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 42 EUROPE: RSV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2015–2022 (USD MILLION)
Table 43 RSV DIAGNOSIS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2015–2022 (USD MILLION)
Table 44 NORTH AMERICA: RSV DIAGNOSIS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 45 EUROPE: RSV DIAGNOSIS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2015–2022 (USD MILLION)
Table 46 RSV DIAGNOSIS MARKET FOR HOME CARE, BY REGION, 2015–2022 (USD MILLION)
Table 47 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR HOME CARE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 48 EUROPE: RSV DIAGNOSTICS MARKET FOR HOME CARE, BY REGION, 2015–2022 (USD MILLION)
Table 49 RSV DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 50 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 51 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 52 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 53 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 54 US: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 55 US: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 56 US: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 57 CANADA: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 58 CANADA: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 59 CANADA: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 60 EUROPE: RSV DIAGNOSTICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 61 EUROPE: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 62 EUROPE: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 63 EUROPE: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 64 GERMANY: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 65 GERMANY: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 66 GERMANY: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 67 UK: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 68 UK: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 69 UK: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 70 FRANCE: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 71 FRANCE: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 72 FRANCE: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 73 ROE: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 74 ROE: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 75 ROE: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 76 APAC: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 77 APAC: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 78 APAC: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 79 ROW: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 80 ROW: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 81 ROW: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 82 SHARE OF COMPANIES IN THE RSV DIAGNOSTICS MARKET (2016)
Table 83 PRODUCT APPROVALS AND LAUNCHES, 2014–2018
Table 84 ACQUISITIONS, 2014–2018
Table 85 AGREEMENTS AND COLLABORATIONS, 2014–2018
Table 86 EXPANSIONS, 2014–2018
Table 1 CURRENT STATUS OF RSV VACCINES
Table 2 RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 3 RSV DIAGNOSTICS MARKET FOR KITS AND ASSAYS, BY REGION, 2015–2022 (USD MILLION)
Table 4 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR KITS AND ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 5 EUROPE: RSV DIAGNOSTICS MARKET FOR KITS AND ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 6 RSV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2015–2022 (USD MILLION)
Table 7 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 8 EUROPE: RSV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 9 RSV DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2015–2022 (USD MILLION)
Table 10 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 11 EUROPE: RSV DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 12 RSV DIAGNOSTICS MARKET, BY METHOD, 2015–2022 (USD MILLION)
Table 13 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 14 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 15 EUROPE: MOLECULAR DIAGNOSTIC MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 16 RAPID ANTIGEN DETECTION TESTS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 17 RAPID ANTIGEN DETECTION TESTS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 18 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 19 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 20 RAPID ANTIGEN DETECTION TESTS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2015–2022 (USD MILLION)
Table 21 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 22 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 23 RAPID ANTIGEN DETECTION TESTS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY REGION, 2015–2022 (USD MILLION)
Table 24 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 25 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 26 OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 27 OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 28 NORTH AMERICA: OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 29 EUROPE: OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 30 RAPID ANTIGEN DETECTION TESTS MARKET FOR CHROMATOGRAPHIC IMMUNOASSAYS, BY REGION, 2015–2022 (USD MILLION)
Table 31 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR CHROMATOGRAPHIC IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 32 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR CHROMATOGRAPHIC IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 33 RAPID ANTIGEN DETECTION TESTS MARKET FOR OPTICAL IMMUNOASSAYS, BY REGION, 2015–2022 (USD MILLION)
Table 34 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR OPTICAL IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 35 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR OPTICAL IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 36 OTHER METHODS MARKET FOR RSV DIAGNOSTICS, BY REGION, 2015–2022 (USD MILLION)
Table 37 NORTH AMERICA: OTHER METHODS MARKET FOR RSV DIAGNOSTICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 38 EUROPE: OTHER METHODS MARKET FOR RSV DIAGNOSTICS, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
Table 39 RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 40 RSV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2015–2022 (USD MILLION)
Table 41 NORTH AMERICA: RSV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 42 EUROPE: RSV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2015–2022 (USD MILLION)
Table 43 RSV DIAGNOSIS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2015–2022 (USD MILLION)
Table 44 NORTH AMERICA: RSV DIAGNOSIS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 45 EUROPE: RSV DIAGNOSIS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2015–2022 (USD MILLION)
Table 46 RSV DIAGNOSIS MARKET FOR HOME CARE, BY REGION, 2015–2022 (USD MILLION)
Table 47 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR HOME CARE, BY COUNTRY, 2015–2022 (USD MILLION)
Table 48 EUROPE: RSV DIAGNOSTICS MARKET FOR HOME CARE, BY REGION, 2015–2022 (USD MILLION)
Table 49 RSV DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 50 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 51 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 52 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 53 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 54 US: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 55 US: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 56 US: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 57 CANADA: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 58 CANADA: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 59 CANADA: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 60 EUROPE: RSV DIAGNOSTICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 61 EUROPE: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 62 EUROPE: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 63 EUROPE: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 64 GERMANY: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 65 GERMANY: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 66 GERMANY: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 67 UK: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 68 UK: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 69 UK: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 70 FRANCE: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 71 FRANCE: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 72 FRANCE: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 73 ROE: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 74 ROE: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 75 ROE: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 76 APAC: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 77 APAC: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 78 APAC: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 79 ROW: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION)
Table 80 ROW: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION)
Table 81 ROW: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 82 SHARE OF COMPANIES IN THE RSV DIAGNOSTICS MARKET (2016)
Table 83 PRODUCT APPROVALS AND LAUNCHES, 2014–2018
Table 84 ACQUISITIONS, 2014–2018
Table 85 AGREEMENTS AND COLLABORATIONS, 2014–2018
Table 86 EXPANSIONS, 2014–2018
LIST OF FIGURES
Figure 1 RESEARCH DESIGN
Figure 2 BOTTOM-UP APPROACH
Figure 3 TOP-DOWN APPROACH
Figure 4 DATA TRIANGULATION METHODOLOGY
Figure 5 RSV DIAGNOSTICS MARKET, BY PRODUCT, 2017 VS. 2022 (USD BILLION)
Figure 6 RSV DIAGNOSTICS MARKET, BY METHOD, 2017 VS. 2022 (USD BILLION)
Figure 7 RSV DIAGNOSTICS MARKET, BY END USER, 2017 VS. 2022 (USD BILLION)
Figure 8 RSV DIAGNOSTICS MARKET, BY REGION, 2017 VS. 2022 (USD BILLION)
Figure 9 INCREASING INCIDENCES OF RSV INFECTION AND INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS ARE DRIVING THE GROWTH OF THE RSV DIAGNOSTICS MARKET
Figure 10 MOLECULAR DIAGNOSTICS IS ESTIMATED TO COMMAND THE LARGEST MARKET SHARE IN 2017
Figure 11 HOSPITALS AND CLINICS TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
Figure 12 APAC TO REGISTER THE HIGHEST CAGR BETWEEN 2017 & 2022
Figure 13 RSV DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND THREATS
Figure 14 KITS AND ASSAYS SEGMENT WILL CONTINUE TO DOMINATE THE RSV DIAGNOSTICS MARKET IN 2022
Figure 15 MOLECULAR DIAGNOSTICS SEGMENT WILL CONTINUE TO DOMINATE THE RSV DIAGNOSTICS MARKET IN 2022
Figure 16 HOSPITALS AND CLINICS SEGMENT WILL CONTINUE TO DOMINATE THE RSV DIAGNOSTICS MARKET IN 2022
Figure 17 APAC TO REGISTER THE HIGHEST GROWTH IN THE RSV DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
Figure 18 NORTH AMERICA: RSV DIAGNOSTICS MARKET SNAPSHOT
Figure 19 EUROPE: RSV DIAGNOSTICS MARKET SNAPSHOT
Figure 20 APAC: RSV DIAGNOSTICS MARKET SNAPSHOT
Figure 21 ROW: RSV DIAGNOSTICS MARKET SNAPSHOT
Figure 22 PRODUCT LAUNCHES, THE MOST ADOPTED GROWTH STRATEGY FROM 2014 TO 2018
Figure 23 BIOM?RIEUX: COMPANY SNAPSHOT (2016)
Figure 24 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2016)
Figure 25 ABBOTT: COMPANY SNAPSHOT
Figure 26 ROCHE: COMPANY SNAPSHOT (2016)
Figure 27 DANAHER: COMPANY SNAPSHOT
Figure 28 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
Figure 29 BIOCARTIS: COMPANY SNAPSHOT (2016)
Figure 30 LUMINEX: COMPANY SNAPSHOT (2016)
Figure 31 HOLOGIC: COMPANY SNAPSHOT (2016)
Figure 1 RESEARCH DESIGN
Figure 2 BOTTOM-UP APPROACH
Figure 3 TOP-DOWN APPROACH
Figure 4 DATA TRIANGULATION METHODOLOGY
Figure 5 RSV DIAGNOSTICS MARKET, BY PRODUCT, 2017 VS. 2022 (USD BILLION)
Figure 6 RSV DIAGNOSTICS MARKET, BY METHOD, 2017 VS. 2022 (USD BILLION)
Figure 7 RSV DIAGNOSTICS MARKET, BY END USER, 2017 VS. 2022 (USD BILLION)
Figure 8 RSV DIAGNOSTICS MARKET, BY REGION, 2017 VS. 2022 (USD BILLION)
Figure 9 INCREASING INCIDENCES OF RSV INFECTION AND INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS ARE DRIVING THE GROWTH OF THE RSV DIAGNOSTICS MARKET
Figure 10 MOLECULAR DIAGNOSTICS IS ESTIMATED TO COMMAND THE LARGEST MARKET SHARE IN 2017
Figure 11 HOSPITALS AND CLINICS TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
Figure 12 APAC TO REGISTER THE HIGHEST CAGR BETWEEN 2017 & 2022
Figure 13 RSV DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND THREATS
Figure 14 KITS AND ASSAYS SEGMENT WILL CONTINUE TO DOMINATE THE RSV DIAGNOSTICS MARKET IN 2022
Figure 15 MOLECULAR DIAGNOSTICS SEGMENT WILL CONTINUE TO DOMINATE THE RSV DIAGNOSTICS MARKET IN 2022
Figure 16 HOSPITALS AND CLINICS SEGMENT WILL CONTINUE TO DOMINATE THE RSV DIAGNOSTICS MARKET IN 2022
Figure 17 APAC TO REGISTER THE HIGHEST GROWTH IN THE RSV DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
Figure 18 NORTH AMERICA: RSV DIAGNOSTICS MARKET SNAPSHOT
Figure 19 EUROPE: RSV DIAGNOSTICS MARKET SNAPSHOT
Figure 20 APAC: RSV DIAGNOSTICS MARKET SNAPSHOT
Figure 21 ROW: RSV DIAGNOSTICS MARKET SNAPSHOT
Figure 22 PRODUCT LAUNCHES, THE MOST ADOPTED GROWTH STRATEGY FROM 2014 TO 2018
Figure 23 BIOM?RIEUX: COMPANY SNAPSHOT (2016)
Figure 24 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2016)
Figure 25 ABBOTT: COMPANY SNAPSHOT
Figure 26 ROCHE: COMPANY SNAPSHOT (2016)
Figure 27 DANAHER: COMPANY SNAPSHOT
Figure 28 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
Figure 29 BIOCARTIS: COMPANY SNAPSHOT (2016)
Figure 30 LUMINEX: COMPANY SNAPSHOT (2016)
Figure 31 HOLOGIC: COMPANY SNAPSHOT (2016)
